MMC 609 Mayo
420 Delaware St. SE
Minneapolis, MN 55455
Leo T. Furcht, M.D.
Allen-Pardee Professor and Head, Department of Laboratory Medicine and Pathology
In addition to his position as head of the Department of Laboratory Medicine and Pathology, Dr. Furcht is chairman of the Board of Directors, University of Minnesota Physicians and President-elect FASEB. He also has held a Research Career development award and MERIT award from the NCI.
- tumor cell behavior
- extracellular matrix protein expression
- cell adhesion molecules
- wound healing
- Columbia University, New York, NY (1964), B.S. (Pre-Medicine)
- SUNY Upstate Medical Center, Syracuse, NY (1972), M.D.
- University of Minnesota (1975), Residency (Clinical Pathology)
- Member, A.O.A. National Medical Honor Society, 1971
- Assistant-Associate Professor, University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, 1975 - 1982
- Professor, University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, 1982 - present
- Endowed Chair, "Allen-Pardee Professor", University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, 1987 - present
- Head, University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, 1990 - present
- Member, University of Minnesota Cancer Center, 1994 - present
- Director and Founder, University of Minnesota, Biomedical Engineering Center, 1989 - 1997
- Director, University of Minnesota, Institute of Medical Biotechnology, 1998 - 2001
- Chairman of the Board, University of Minnesota Physicians, 2004 - present
- Recipient Research Career Development Award, NCI/NIH, 1980 - 1985
- Member, Pathology B Study Section Permanent; various ad hoc study sections, NIH, 1982 - 1986
- Recipient NIH/NCI MERIT Award: "Molecular Mechanisms in Metastasis", NIH, 1989 - present
- Member, Pathobiochemistry Study Section, NIH, 1990 - 1993
- NCI Study Section on Program Project - Parent Committee Member, NIH, 1995 - 1999
Dr. Furcht has extensively published in the areas of the role of chondroitin surface glycosaminoglycan binding site in a4b1 integrin-mediated melanoma cell adhesions, the inhibition of melanoma cell binding to type IV collagen by analogs of CAR, laminin peptide amelioration of brain injury by inhibiting leukocyte accumulation in a rat model of transient focal cerebral ischemia, antagonism of leukocyte adherence by synthetic fibronectin peptide V in a rat model of transient focal cerebral ischemia and the effects of lovastatin on [3H] thymidine uptake in HTC-4 and LLC-L1 tumor cells.
- Furcht, L.T., and Hoffman, W. Stem Cells. Minnesota Health Care News, 7(3), March 2009.
- Furcht, L.T., and Wolinetz, D.C. What cures will we miss? The effects of reduced funding for biomedical research. Minnesota Health Care News, 6(1), January 2008.
- Furcht, L.T. NIH funding: what does the future look like? [Comment letter]. Science, 316:198-200, April 13, 2007.
- Furcht, L.T. and Wolinetz, C.D. What cures will we miss? The effects of reduced funding for biomedical research. Minnesota Physician, XXI (5), August 2007.
- Brockway, L.M. and Furcht, L.T. Conflicts of interest in biomedical research-the FASEB guidelines. The FASEB Journal, 20, 2435-2438, 2006.
- Brockway LM. and Furcht, L.T. Financial disclosure policies of scientific publications. [Comment letter]. JAMA, 296(4): 2925-6: author reply 2926, 2006.
- Delarco, J.E., Wuertz, B.R., Furcht, L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer Research. 10(15):4895-900, 2004.
- Iida, J., Wilhelmson, K.L., Price, M.A., Wilson, C.M., Pei, D., Furcht, L.T., McCarthy, J.B. Membrane type-1 matrix matalloproteinase promotes human melanoma invasion and growth. J. of Investigative Dermatology. 122(1):167-76, 2004.
For a full list of Dr. Furcht's publications, Search PubMed.